London: Savara said on Wednesday its experimental therapy met the main goal of a late-stage trial by improving a measure of lung function in patients with a rare disease that causes breathing difficulties, sending its shares up 31 per cent.

The therapy is being developed to treat patients with autoimmune pulmonary alveolar proteinosis (aPAP), which can lead to shortness of breath, cause scarring in the lungs and even lead to a need for a lung transplant.

The disease is estimated to affect less than 5,000 people in the United States, according to government data.

Savara’s inhaled therapy, molgramostim, helped improve a measure of lung capacity that tracks the ability of the lungs to transfer gas from inhaled air to red blood cells in blood capillaries in the lung, compared with a placebo.

Molgramostim was well-tolerated and the frequency of adverse events was generally similar between treatment groups, the drug developer said.

Savara plans to submit a marketing application for the therapy in the first half of 2025.

(Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid and Devika Syamnath)

  • Published On Jun 26, 2024 at 05:50 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App